|
|
Post by markado on Mar 1, 2023 10:25:13 GMT -5
After the $35 reduction/cap in price on their insulins? Let me count the ways...
|
|
|
|
Post by prcgorman2 on Mar 1, 2023 11:19:53 GMT -5
Shorting MNKD?
|
|
|
|
Post by markado on Mar 1, 2023 13:09:50 GMT -5
I don't think the $170M short play on MNKD would touch the anticipated revenue hit from this price cap. No, they just might need something else to actually sell in their (US or Worldwide) bag. |
|
|
|
Post by cretin11 on Mar 1, 2023 13:18:54 GMT -5
I don't think the $170M short play on MNKD would touch the anticipated revenue hit from this price cap. No, they just might need something else to actualky sell in their (US or Worldwide) bag. Maybe we could sell them V-Go for their bag!  |
|
|
|
Post by prcgorman2 on Mar 1, 2023 13:30:33 GMT -5
I don't think the $170M short play on MNKD would touch the anticipated revenue hit from this price cap. No, they just might need something else to actualky sell in their (US or Worldwide) bag. Maybe we could sell them V-Go for their bag! The surest sign of no concern for those with invested interest is playing the fiddle while Rome burns. |
|
|
|
Post by peppy on Mar 1, 2023 13:58:38 GMT -5
Maybe we could sell them V-Go for their bag! The surest sign of no concern for those with invested interest is playing the fiddle while Rome burns.Per CNBC, Novo Nordisk and Sanofi are not following the Eli Lilly $35 dollar insulin price cap. ================================================================= Jan 24, 2020 Novo Nordisk recently rolled out its promised insulin price cuts, along with a new free emergency supply option. The diabetes drug maker delivered on two earlier announced plans—generic options and a $99-per-month, with-or-without insurance plan—along with an “Immediate Supply” program. Novo's new free, one-time emergency supply would give three vials or two packs of pens, or about a one-month supply, to people with prescriptions who may be at risk of rationing. The My$99Insulin program offers a similar three vials or two packs of pens on any Novo Nordisk insulins at a cost of $99 per month, while the generic or follow-on insulin is priced between $145 and $279 depending on the brand. |
|
limo
Researcher
Posts: 82
|
Post by limo on Mar 1, 2023 15:00:49 GMT -5
NOVO NORDISK – Eli Lilly news small for Novo's. New York Times says ‘’Eli Lilly said it would cut the price of insulin, capping the monthly out-of-pocket cost of the lifesaving drug at $35’’. WE say: US insulin business is less than 5% of revenue for NOVO (It’s all about GLP, and Obesity). And Eli's price cut is on list prices not net prices. Not important for the growth case in Novo.
(Broker comment from one of their analysts)
|
|
|
|
Post by peppy on Mar 1, 2023 15:10:07 GMT -5
NOVO NORDISK – Eli Lilly news small for Novo's. New York Times says ‘’Eli Lilly said it would cut the price of insulin, capping the monthly out-of-pocket cost of the lifesaving drug at $35’’. WE say: US insulin business is less than 5% of revenue for NOVO (It’s all about GLP, and Obesity). And Eli's price cut is on list prices not net prices. Not important for the growth case in Novo. (Broker comment from one of their analysts) Yes, Novo Nordisk and Sanofi have the EU contracts. |
|
|
|
Post by prcgorman2 on Mar 1, 2023 15:26:10 GMT -5
And they've other drugs to sell...
|
|
limo
Researcher
Posts: 82
|
Post by limo on Mar 1, 2023 15:33:23 GMT -5
Sorry no the US is their largest market for insulin
|
|
|
|
Post by peppy on Mar 1, 2023 15:39:48 GMT -5
Sorry no the US is their largest market for insulin Limo, may I please ask with statements like this please post the financial page and the quarterly filing in support. I assume you are referring to NVO and Sanofi? |
|
limo
Researcher
Posts: 82
|
Post by limo on Mar 1, 2023 16:23:07 GMT -5
Sorry no the US is their largest market for insulin Limo, may I please ask with statements like this please post the financial page and the quarterly filing in support. I assume you are referring to NVO and Sanofi? Sure , I’ll repost in the morning (Uk time) |
|
|
|
Post by sayhey24 on Mar 1, 2023 16:34:14 GMT -5
I don't think the $170M short play on MNKD would touch the anticipated revenue hit from this price cap. No, they just might need something else to actualky sell in their (US or Worldwide) bag. Help me out here - Lilly is now giving away Humalog, how is that impacting afrezza? It kills Novolog both on Medicare and commercially. CMS (Medicare) will still need to include forms "vial, pen and inhaled" in their bid package and there is only one "inhaled" vendor. We have already seen from the ABC study, afrezza kicks butt on the RAAs and once the Big study is done should be the Standard of Care. CGMs are positioned to be approved for once daily insulin which will expose the GLP1s for what they are post meal and we already know the RAAs lose to afrezza. If Medicare is 40% of the market thats 40% more than afrezza has today. By killing Humalog and Novolog there is no incentive to sell them so the reps won't be buying free lunches for the doctors and could careless if afrezza replaces them. Whats the afrezza impact or does this help afrezza? |
|
|
|
Post by peppy on Mar 1, 2023 16:49:56 GMT -5
I don't think the $170M short play on MNKD would touch the anticipated revenue hit from this price cap. No, they just might need something else to actualky sell in their (US or Worldwide) bag. Help me out here - Lilly is now giving away Humalog, how is that impacting afrezza? It kills Novolog both on Medicare and commercially. CMS (Medicare) will still need to include forms "vial, pen and inhaled" in their bid package and there is only one "inhaled" vendor. We have already seen from the ABC study, afrezza kicks butt on the RAAs and once the Big study is done should be the Standard of Care. CGMs are positioned to be approved for once daily insulin which will expose the GLP1s for what they are post meal and we already know the RAAs lose to afrezza. If Medicare is 40% of the market thats 40% more than afrezza has today. By killing Humalog and Novolog there is no incentive to sell them so the reps won't be buying free lunches for the doctors and could careless if afrezza replaces them. Whats the afrezza impact or does this help afrezza? Seems to me MNKD has to match the $35 price at least for the four unit pack. That said, subq insulin at $35 a month the pharmacy purchasing managers can't be expecting a rebate for prescription can they? If pharmacy purchasing managers are no longer getting a rebate, why would they care, Humalog at $35 or Afrezza at $35? sayhey24 , the amount of insulin type twos need, and endo's reluctant to put them on insulin.... Type 1's at $35 dollars a month, insured, non-insured, old, what is the barrier now? The Rx? The desire? At $35 dollars, try it, you'll like it? See if Mikey likes it, he'll try anything? |
|
|
|
Post by sayhey24 on Mar 1, 2023 17:15:09 GMT -5
Peppy - Why "MNKD has to match the $35 price at least for the four unit pack" for what Medicare? They are selling very little commercially.
The insurance companies are required to cover a form of "inhaled" insulin for Medicare. They contact the vendor(MNKD) and get a price - lets say $1000. They then incorporate this price into their bid back to CMS for providing Plan D coverage. However in the fomularity it is listed for $35 - whatever a 30 day supply is and that is what the patient pays - not the $1000+.
For RAA vial - Lilly will respond to the request from the insurance companies with $35 for Humalog. The insurance company will plus up the $35 with their costs and respond in their bid with that number. The PWD pays $35.
Commercially the few who get insurance to cover will continue to and the rest will buy direct as they are today for $99.
Lets remember afrezza is not Humalog and should not be spoken in the same sentence. They are night and day for controlling post prandial glucose. The best RAA will do is the AID and what we saw in the ABC trial is it clearly failed.
For doctors and T2s, why are they not prescribing insulin??? Hypos. They can kill people with the subqs. Whats the chance of getting a severe hypo with afrezza as long as your liver is OK and you don't go crazy inhaling??? Maybe not zero but pretty close. No RAA can claim that. Thats the market Mike is currently not addressing but has huge potential especially when the CGMs get approved with no RAA cover.
|
|
